Affiliation:
1. From the Centre for Health Economics, University of York, York, United Kingdom
Abstract
In Europe, the vast majority of the costs of cancer therapy fall on third-party payers, normally the government, or sickness funds. Therefore, the main focus of cost-effectiveness studies is to assist payers in deciding whether new therapies are worthwhile, despite their high cost. Drug budgets are regulated in most European countries. The main form of central control is price setting, with some form of reference pricing being the most common approach. This sets the price of drugs, either to an international standard, or to a common price for drugs in the same group or cluster. At the hospital level, the main control over cancer drugs is the hospital formulary. Studies have shown a wide variation among European countries in access to cancer drugs. Explanations for these variations include differences in research funding, the drug approval process, the role of health economics in decision making, and budgetary issues. Several countries in Europe now require economic data in making decisions about the reimbursement of new drugs. An examination of decisions made by the National Institute for Health and Clinical Excellence in the United Kingdom suggests that cancer drugs have fared quite well, with most recommendations being positive. This could be because of the seriousness of the health condition and the lack of alternative therapies for some cancer patients. If the policy of requesting cost-effectiveness evidence for pricing and reimbursement decisions becomes more popular, a major implication for the pharmaceutical industry is that studies should be conducted during phase III of clinical development to generate the required data.
Publisher
American Society of Clinical Oncology (ASCO)
Reference5 articles.
1. Value in Health: “Bridging the Gap” Among Our Disciplines
2. Wilking N, Jönsson B: A pan-European comparison regarding patient access to cancer drugs . Stockholm, Sweden, Karolinska Institutet in collaboration with Stockholm School of Economics, 2005
3. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews
4. Newdick C: Evaluating new health technology in the English National Health Service, in Jost TS (ed): Health Care Coverage Determinations: An International Comparative Study . Maidenhead, England, Open University Press, 2005
5. National Institute for Clinical Excellence and its value judgments
Cited by
106 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献